6:05 PM
 | 
Feb 21, 2013
 |  BC Extra  |  Company News

UCB, ConfometRx in GPCR discovery deal

UCB Group (Euronext:UCB) and structural biology company ConfometRx (Santa Clara, Calif.) partnered to research GPCR modulation to discover new therapies for neuroscience...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >